Zobrazeno 1 - 10
of 61
pro vyhledávání: '"adjuvanted recombinant zoster vaccine"'
Autor:
Xinghuo Pang, O’Mareen Spence, Neeraj Parmar, Jing Wang, Tao Zhou, Xiang Guo, Audrey Colliou, Sheela Pradeep Sarang, Mitra Yousefi, Huifeng Yun
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)
This post-marketing surveillance study evaluated the safety of the adjuvanted recombinant zoster vaccine (RZV) in Chinese adults, given the limited country-specific safety data accumulated since the 2019 licensure of RZV in China for adults ≥ 50 ye
Externí odkaz:
https://doaj.org/article/5b492fbdf8494550946770f8be25ad65
Autor:
Diana Alexandra Echeverria Proano, Fengcai Zhu, Xiaodong Sun, Jesús Zoco, Jyoti Soni, Neeraj Parmar, S. Omar Ali
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)
Phase III multi-country studies (ZOE-50/70) demonstrated that the adjuvanted recombinant zoster vaccine (RZV) was well tolerated and prevented herpes zoster (HZ) in healthy ≥ 50-year-olds, with a vaccine efficacy (VE) > 90% across age groups. These
Externí odkaz:
https://doaj.org/article/378899e3d99746fbae93898ecd90c44b
Autor:
Edward A. Stadtmauer, Keith M. Sullivan, Mohamed El Idrissi, Bruno Salaun, Aránzazu Alonso Alonso, Charalambos Andreadis, Veli-Jukka Anttila, Adrian JC Bloor, Raewyn Broady, Claudia Cellini, Antonio Cuneo, Alemnew F. Dagnew, Emmanuel Di Paolo, HyeonSeok Eom, Ana Pilar González-Rodríguez, Andrew Grigg, Andreas Guenther, Thomas C. Heineman, Isidro Jarque, Jae-Yong Kwak, Alessandro Lucchesi, Lidia Oostvogels, Marta Polo Zarzuela, Anne E. Schuind, Thomas C. Shea, Ulla Marjatta Sinisalo, Filiz Vural, Lucrecia Yáñez San Segundo, Pierre Zachée, Adriana Bastidas
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 17, Iss 11, Pp 4144-4154 (2021)
Immunocompromised individuals, particularly autologous hematopoietic stem cell transplant (auHSCT) recipients, are at high risk for herpes zoster (HZ). We provide an in-depth description of humoral and cell-mediated immune (CMI) responses by age (pro
Externí odkaz:
https://doaj.org/article/c5297d7339fc47679ada3fceed31e22b
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 17, Iss 11, Pp 4132-4143 (2021)
Immunocompromised (IC) persons are at increased risk for herpes zoster (HZ) and its complications, mainly due to impairment of cell-mediated immunity (CMI). The adjuvanted recombinant zoster vaccine (RZV) demonstrated efficacy against HZ in autologou
Externí odkaz:
https://doaj.org/article/4e3aa43ba5b54c61893201423fd6e997
Autor:
Joon Hyung Kim, John Diaz-Decaro, Ning Jiang, Shinn-Jang Hwang, Eun Ju Choo, Maribel Co, Andrew Hastie, David Shu Cheong Hui, Junya Irimajiri, Jacob Lee, Edward Man-Fuk Leung, Haiwen Tang, Tomomi Tsuru, Philip Watson, Zhenhua Wu, Chong-Jen Yu, Yanfei Yuan, Toufik Zahaf, Anthony L. Cunningham, Anne Schuind
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 17, Iss 7, Pp 2050-2057 (2021)
In two large clinical trials (ZOE-50 [NCT01165177] and ZOE-70 [NCT01165229]), two doses of the adjuvanted recombinant zoster vaccine (RZV) demonstrated >90% efficacy (VE) against herpes zoster (HZ) in adults ≥50 years of age (YOA). This post-hoc an
Externí odkaz:
https://doaj.org/article/3f26a5280f08465fa9cb53f30f8d89cb
Autor:
Desmond Curran, Melissa K. Andrew, Myron J. Levin, Elisa Turriani, Sean Matthews, Charles Fogarty, Nicola P. Klein, Katrijn Grupping, Lidia Oostvogels, Kenneth E. Schmader
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 15, Iss 12, Pp 2960-2968 (2019)
Frail older adults are at increased risk of poor clinical outcomes. Frailty assessment is therefore important in clinical trials to understand the benefits and harms of interventions. However, consensus is lacking on how frailty should be assessed. W
Externí odkaz:
https://doaj.org/article/56287ad8fafd48bbab247f31b6a0ae1b
Autor:
Lidia Oostvogels, Thomas C. Heineman, Robert W. Johnson, Myron J. Levin, Janet E. McElhaney, Peter Van den Steen, Toufik Zahaf, Alemnew F. Dagnew, Roman Chlibek, Javier Diez-Domingo, Iris S. Gorfinkel, Caroline Hervé, Shinn-Jang Hwang, Hideyuki Ikematsu, George Kalema, Himal Lal, Shelly A. McNeil, Tomas Mrkvan, Karlis Pauksens, Jan Smetana, Daisuke Watanabe, Lily Yin Weckx, Anthony L. Cunningham
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 15, Iss 12, Pp 2865-2872 (2019)
In two pivotal efficacy studies (ZOE-50; ZOE-70), the adjuvanted recombinant zoster vaccine (RZV) demonstrated >90% efficacy against herpes zoster (HZ). Adults aged ≥50 or ≥70 years (ZOE-50 [NCT01165177]; ZOE-70 [NCT01165229]) were randomized to
Externí odkaz:
https://doaj.org/article/2de77cc0739443df82239135c7c026b5
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.